1 |
dpavlin |
1.3 |
|
2 |
|
|
<p align="left"><font size="4" color="#FF9933"><b><img src="t/development.gif" width="225" height="16"></b></font></p> |
3 |
|
|
<table width="90%" border="0" cellspacing="0" cellpadding="0" align="center"> |
4 |
|
|
<tr> |
5 |
|
|
<td height="10" width="19%"> |
6 |
|
|
<div align="center"><b>PROJECT</b></div> |
7 |
|
|
</td> |
8 |
|
|
<td height="10" width="26%"> |
9 |
|
|
<div align="center"><b>INDICATION</b></div> |
10 |
|
|
</td> |
11 |
|
|
<td height="10" width="24%"> |
12 |
|
|
<div align="center"><b>STATUS</b></div> |
13 |
|
|
</td> |
14 |
|
|
</tr> |
15 |
|
|
</table> |
16 |
|
|
<table width="90%" border="1" cellspacing="0" cellpadding="0" align="center"> |
17 |
|
|
<tr> |
18 |
|
|
<td width="19%"> |
19 |
|
|
<div align="center">PLD - 116</div> |
20 |
|
|
</td> |
21 |
|
|
<td width="26%"> |
22 |
|
|
<div align="center">Inflammatory Bowel Disease (IBD)</div> |
23 |
|
|
</td> |
24 |
|
|
<td width="24%"> |
25 |
|
|
<div align="center">Clinical Trials</div> |
26 |
|
|
</td> |
27 |
|
|
</tr> |
28 |
|
|
<tr> |
29 |
|
|
<td width="19%"> |
30 |
|
|
<div align="center">PLD - 117</div> |
31 |
|
|
</td> |
32 |
|
|
<td width="26%"> |
33 |
|
|
<div align="center">Oncology<br> |
34 |
|
|
Hematology</div> |
35 |
|
|
</td> |
36 |
|
|
<td width="24%"> |
37 |
|
|
<div align="center">Clinical Trials</div> |
38 |
|
|
</td> |
39 |
|
|
</tr> |
40 |
|
|
<tr> |
41 |
|
|
<td width="19%"> |
42 |
|
|
<div align="center">PLD - 118</div> |
43 |
|
|
</td> |
44 |
|
|
<td width="26%"> |
45 |
|
|
<div align="center">Anti-fungal</div> |
46 |
|
|
</td> |
47 |
|
|
<td width="24%"> |
48 |
|
|
<div align="center">Clinical Trials</div> |
49 |
|
|
</td> |
50 |
|
|
</tr> |
51 |
|
|
<tr> |
52 |
|
|
<td width="19%"> |
53 |
|
|
<div align="center">PLR - 1</div> |
54 |
|
|
</td> |
55 |
|
|
<td width="26%"> |
56 |
|
|
<div align="center">Anti-infective</div> |
57 |
|
|
</td> |
58 |
|
|
<td width="24%"> |
59 |
|
|
<div align="center">Discovery</div> |
60 |
|
|
</td> |
61 |
|
|
</tr> |
62 |
|
|
<tr> |
63 |
|
|
<td width="19%"> |
64 |
|
|
<div align="center">PLR - 13</div> |
65 |
|
|
</td> |
66 |
|
|
<td width="26%"> |
67 |
|
|
<div align="center">Inflammation<br> |
68 |
|
|
Asthma</div> |
69 |
|
|
</td> |
70 |
|
|
<td width="24%"> |
71 |
|
|
<div align="center">Discovery</div> |
72 |
|
|
</td> |
73 |
|
|
</tr> |
74 |
|
|
<tr> |
75 |
|
|
<td width="19%"> |
76 |
|
|
<div align="center">PLR - 9</div> |
77 |
|
|
</td> |
78 |
|
|
<td width="26%"> |
79 |
|
|
<div align="center">Anti-infective</div> |
80 |
|
|
</td> |
81 |
|
|
<td width="24%"> |
82 |
|
|
<div align="center">Discovery</div> |
83 |
|
|
</td> |
84 |
|
|
</tr> |
85 |
|
|
<tr> |
86 |
|
|
<td width="19%"> |
87 |
|
|
<div align="center">PLR - 14</div> |
88 |
|
|
</td> |
89 |
|
|
<td width="26%"> |
90 |
|
|
<div align="center">Inflammation<br> |
91 |
|
|
RA, IBD</div> |
92 |
|
|
</td> |
93 |
|
|
<td width="24%"> |
94 |
|
|
<div align="center">Discovery</div> |
95 |
|
|
</td> |
96 |
|
|
</tr> |
97 |
|
|
</table> |
98 |
|
|
|
99 |
|
|
|
100 |
|
|
<p><b>PLD-116</b></p> |
101 |
dpavlin |
1.4 |
<p>Full Phase I clinical studies of PLD-116 were successfully completed in the EU in the first half of 2001. PLD-116 treatment proved to be well tolerated in thirty-two healthy volunteers. The PLD-116 project was initiated in December 1999 to develop a novel peptide into a drug for the treatment of inflammatory bowel disease. The peptide, derived from a natural protein, provides a novel anti-inflammatory treatment option for inflammatory bowel disease.</p> |
102 |
dpavlin |
1.3 |
<p><b>PLD-117</b></p> |
103 |
|
|
<p>In 1999 PLIVA signed a licensing agreement with <a |
104 |
|
|
href="http://www.receptron.com">Receptron, Inc.</a>, a |
105 |
|
|
Californian based Biotech Company, and acquired exclusive worldwide rights to |
106 |
|
|
develop and market the PLD-117 peptide with TPO-like activity. The |
107 |
|
|
peptide PLD-117 for the treatment of thrombocytopenia, a severe complication |
108 |
|
|
of cancer chemotherapy, was brought to clinical study trials in the USA in December |
109 |
|
|
2000. The proposed treatment is based on a unique approach using peptide that |
110 |
|
|
activates thrombopoietin (TPO) receptor.</p> |
111 |
|
|
<p><b>PLD-118</b></p> |
112 |
dpavlin |
1.4 |
<p>The licensed-in novel antifungal agent PLD-118 was successfully brought into clinical development ahead of schedule in November 2000. Two Phase I clinical studies of PLD-118 were successfully completed in the EU in August 2001. PLD-118 has the potential to be the first novel oral antifungal for the treatment of Candida infections since the introduction of azoles in the 80's.</p> |